Colchicine poisoning: the dark side of an ancient drug.
Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, Pollak U, Koren G, Bentur Y.
Clin Toxicol (Phila). 2010 Jun;48(5):407-14. doi: 10.3109/15563650.2010.495348.
Clinical management of patients with drug-induced liver injury (DILI).
Björnsson ES.
United European Gastroenterol J. 2021 Sep;9(7):781-786. doi: 10.1002/ueg2.12113. Epub 2021 Jun 28.
Hepatotoxicity of erythromycin.
Braun P.
J Infect Dis. 1969 Mar;119(3):300-6. doi: 10.1093/infdis/119.3.300.
Erythromycin-associated cholestatic hepatitis.
Derby LE, Jick H, Henry DA, Dean AD.
Med J Aust. 1993 May 3;158(9):600-2. doi: 10.5694/j.1326-5377.1993.tb137625.x.
Clarithromycin-haltige H.-pylori-Therapie birgt höheres Risiko für akute neuropsychiatrische Ereignisse.
Plate A.
Praxis (Bern 1994). 2016 Sep;105(18):1103-4. doi: 10.1024/1661-8157/a002469.
Telithromycin.
Turner M, Corey GR, Abrutyn E.
Ann Intern Med. 2006 Mar 21;144(6):447-8. doi: 10.7326/0003-4819-144-6-200603210-00014.
Clarithromycin-induced hepatotoxicity.
Brown BA, Wallace RJ Jr, Griffith DE, Girard W.
Clin Infect Dis. 1995 Apr;20(4):1073-4. doi: 10.1093/clinids/20.4.1073.
Azithromycin-Induced Cholestatic Hepatitis.
Moy BT, Dojki FK, Scholes JV, Hoffman MG.
Conn Med. 2015 Apr;79(4):213-5.
Erythromycin ototoxicity.
McGhan LJ, Merchant SN.
Otol Neurotol. 2003 Jul;24(4):701-2. doi: 10.1097/00129492-200307000-00029.
Macrolides: From Toxins to Therapeutics.
Lenz KD, Klosterman KE, Mukundan H, Kubicek-Sutherland JZ.
Toxins (Basel). 2021 May 12;13(5):347. doi: 10.3390/toxins13050347.
